ArticleTherapeutic advances in medical oncology2019

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma.

Shukui Qin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.